102137-46-2

Basic information

• Product Name: 4-(pyridin-2-ylmethoxy)aniline
• Synonyms: 4-(pyridin-2-ylmethoxy)aniline;Albb-005559;4-(pyridin-2-ylmethoxy)aniline(SALTDATA: FREE);4-(Pyridine-2ylMethoxy)aniline;[4-(2-pyridylmethoxy)phenyl]amine;4-(2-pyridylmethoxy)aniline;2-[(4-Aminophenoxy)methyl]pyridine
• CAS NO: 102137-46-2
• Molecular Formula: C₁₂H₁₂N₂O
• Molecular Weight: 200.24
• Mol File: 102137-46-2.mol

Chemical Properties

• Boiling Point: 369.5 °C at 760 mmHg
• Flash Point: 177.3 °C
• Appearance: /
• Density: 1.18 g/cm³
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: 4-(pyridin-2-ylmethoxy)aniline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(pyridin-2-ylmethoxy)aniline(102137-46-2)
• EPA Substance Registry System: 4-(pyridin-2-ylmethoxy)aniline(102137-46-2)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 102137-46-2(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
4-(Pyridin-2-ylmethoxy)aniline is used as a key intermediate in the synthesis of various organic compounds due to its structural features, which allow for the formation of diverse chemical entities.
Used in Medicinal Chemistry:
In the pharmaceutical industry, 4-(Pyridin-2-ylmethoxy)aniline is utilized as a starting material for the development of pharmaceutical agents, given its promising biological activity and potential to be incorporated into therapeutic molecules.
Used as a Ligand in Coordination Chemistry:
4-(Pyridin-2-ylmethoxy)aniline serves as a ligand in coordination chemistry, where it can form complexes with metal ions, contributing to the study and development of new materials with specific properties.
Used in the Preparation of Complex Organic Molecules:
4-(Pyridin-2-ylmethoxy)aniline is employed in the preparation of complex organic molecules, where its unique structural elements can be leveraged to create sophisticated chemical entities for various applications.
Overall, 4-(Pyridin-2-ylmethoxy)aniline is a compound of interest for further research and development across multiple scientific disciplines, including organic synthesis, medicinal chemistry, coordination chemistry, and the creation of complex organic molecules.

Upstream product

• 145654-42-8 2-(4-nitrophenoxymethyl)pyridine 
• 586-98-1 2-Hydroxymethylpyridine 
• 350-46-9 4-Fluoronitrobenzene 
• 852314-54-6 C₁₇H₂₀N₂O₃ 
• 105350-45-6 N-acetyl-4-(pyrid-2-ylmethoxy)aniline 
• 103-90-2 4-acetaminophenol 
• 6959-47-3 2-chloromethylpyridine hydrochloride 

Downstream Products

• 339071-61-3 N-[4-(pyridin-2-ylmethoxy) phenyl]-N'-hydroxyformamidine 
• 936351-48-3 4-(pyridin-2-ylmethoxy)-phenylamine hydrochloride 
• 1393835-36-3 1-(3-morpholinopropyl)-8-(4-(pyridin-2-ylmethoxy)phenylamino)oxazolo[4,5-g]quinazolin-2(1H)-one 
• 1166310-88-8 1-(3-chloropropyl)-3-[4-(2-pyridinylmethoxy)phenyl]urea 
• 1166310-86-6 1-(2-chloroethyl)-3-[4-(2-pyridinylmethoxy)phenyl]urea 
• 936801-69-3 ethyl 6-methyl-5-(4-(pyridine-2-ylmethoxy)phenylcarbamoyl)-nicotinate 
• 936801-62-6 2-methyl-5-nitro-N-[4-(pyridin-2-ylmethoxy)-phenyl]-nicotinamide 

Relevant articles and documents

NAPHTHALENE DERIVATIVE

The present invention provides compounds which can regulate VCP activity. The present invention provides the compound of formula (I) (R is as defined in the description) or oxides, esters, prodrugs, pharmaceutically acceptable salts or solvates thereof. The compounds can regulate VCP activity, and thus are useful for treating VCP-mediated diseases such as neurodegenerative diseases.

BIARYLAMIDE INHIBITORS OF LEUKOTRIENE PRODUCTION

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, C, R1a, R1b, R2, R3, R4a and R4b are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Studies on novel 2-imidazolidinones and tetrahydropyrimidin-2(1H)-ones as potential TACE inhibitors: Design, synthesis, molecular modeling, and preliminary biological evaluation

Compounds belonging to the class of 2-imidazolidinones and tetrahydropyrimidin-2(1H)-ones were synthesized and evaluated for their TACE inhibitory activity. Most of the compounds showed very good TACE inhibitory activity. Docking study clearly indicates importance of the P1′ group of the inhibitor for the TACE inhibitory activity. This work proves that these two classes of molecules could be used as potential leads for the development of TACE inhibitors.

COMPOSITIONS AND TREATMENTS COMPRISING 5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITORS AND NITRIC OXIDE MODULATORS

Disclosed herein are compositions and compounds that combine an inhibitor of 5-lipoxygenase activating protein (FLAP) and a modulator of NO levels in a mammal. The NO modulator can be an agent that induces the production of NO in a mammal, or can be an ag

BICYCLOSULFONYL ACID (BCSA) COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS

This invention pertains generally to the field of therapeutic compounds, and more particularly, to certain bicyclosulfonyl acid (BCSA) compounds which act as inhibitors of Tumour Necrosis Factor-α Converting Enzyme (TACE). The compounds are useful in the

BISAMIDE CYTOKINE INHIBITORS

The present invention provides low molecular weight compounds useful as cytokine inhibitors, and compositions thereof. In particular, compounds of the invention are bisamides and are useful as anti-inflammatory agents. In one aspect the compounds have the

PYRAZOLOPYRIMIDINES AS ANTI - HEPATITS C AGENTS

Pyrazolopyrimidine derivatives of formula (I), or a pharmaceutically acceptable salt thereof, are found to be active against hepatitis C infection, wherein: R1 is C6-C10 aryl, 5- to 10- membered heteroary1, -(C1-C4 alkyl)-(C6-C10 aryl) or -(C1-C4 alkyl)-(5- to 10- membered heteroaryl); R2 is a C6-C10 aryl, C3-C6 carbocyclyl, 5- to 10- membered heteroaryl or 5- to 10- membered heterocyclyl moiety, said moiety being optionally fused to a C6-C10 aryl, C3-C6 carbocyclyl, 5- to 10- membered heteroaryl or 5- to 10-membered heterocyclic ring; and X is -NR'-, -NR'-CO-NR''-, -NR'-L, or -NR'-CO-L-, wherein R' and R'' are the same or different and each represent hydrogen or a C1-C6 alkyl group and L represents a C1-C6 alkylene group, the aryl, heteroaryl, heterocyclyl. and carbocyclyl moieties in the R1 and R2 substituents being unsubstituted or substituted by 1, 2 or 3 substituents selected from halogen, C1-C4 alkyl C1-C4alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, cyano, nitro, C6-C10 aryl, C3-C6 carbocyclyl, 5- to 10- membered heterocyclyl, 5- to 10- membered heteroaryl, -NR'-CO2-R'', -CO2R'', -COR'''-NR'-CO-R''',-CONR'R'',SO2NR'R'',SO2R'''and -O-(CH2)n-R''' substituents, wherein n is from 0 to 4, each R’is the same or different and is hydrogen or C1-C6 alkyl, each R'' is the same or different and is hydrogen, C1-C6 alkyl, C6-C10 aryl, 5- to 10- membered heterocyclyl or 5- to 10- membered heteroaryl, each R''' is the same or different and is C1-C6 alkyl, C6-C10 aryl, 5- to 10- membered heterocyclyl or 5- to 10- membered heteroaryl, and each R'''' is the same or different and is C6-C10 aryl, 5- to 10- membered heterocyclyl or 5- to 10- membered heterocryl, the aryl, heteroaryl, heterocyclyl and carbocyclyl moieties in said substituents being unsubstituted or substituted by a further substituent selected from C1-C4 alkyl, C1-C4 hydroxyalkyl and C1-C4 haloalkyl groups.

1-[2-[(Heteroarylmethoxy)aryl]carbamoyl]indolines are selective and orally active 5-HT(2C) receptor inverse agonists

Bisarylmethoxyethers have been identified with nanomolar 5-HT(2C) affinity and selectivity over both 5-HT(2A) 5-HT(2A) and 5-HT(2B) receptors. Compounds such as 1, 2, 8, 12, 14 and 18 have potent oral activity in a centrally mediated pharmacodynamic model

INDOLE CARBOXYLATE DERIVATIVES WHICH INHIBIT LEUKOTRIENE BIOSYNTHESIS

Compounds of the structure where A is straight or branched divalent alkylene or divalent cycloalkylene, R1 is selected from hydrogen; alkylthio; optionally substituted phenylthio; optionally substituted phenylalkylthio; optionally substituted 2-, 3-, and 4-pyridyl; optionally substituted 2-, and 3-thienylthio; and optionally substituted 2-thiazolythio, R2 is selected from -COOB; -COOalkyl; -COOalkyl(carbocyclic aryl); -CONR5R6 ; -COR6 ; and -OH, R3 is selected from phenylalkyl and heteroarylalkyl, and R4 is selected from optionally substituted alkoxy(carbocyclic aryl); optionally substituted carbocyclic aryloxy; optionally substituted heteroarylalkoxy; and optionally substituted heteroaryloxy are potent inhibitors of lipoxygenase enzymes and thus inhibit the biosynthesis of of leukotrienes. These compounds are useful in the treatment or amelioration of allergic and inflammatory disease states

2-quinolinyl methoxy compounds, medical uses and intermediates therefor

The present invention relates to compounds of formula STR1 in which formula I X stands for O, S, STR2 R1 and R2 which can be the same or different stand for hydrogen, straight or branched, saturated or unsaturated, unsubstituted or substituted C1- C8 -alkyl, aryl or for ar-C1 -C4 -alkyl, aryl and ar being unsubstituted or substituted phenyl; R3, R4, R5, and R6 are the same or different and stand for hydrogen, halogen, pseudo halogen, cyano, nitro, amino, carboxy, hydroxy, alkyl, alkoxy; or R5 and R6 form an aromatic ring which is fused to the pyridyl ring, and which aromatic ring may substituted; provided that R1 and R2 cannot be hydrogen at the same time, and provided that when R5 and R6 both are chlorine and R1 is hydrogen, then R2 cannot be n-propyl; and salts and bioreversible derivatives thereof. The compounds of formula I are useful in the human and veterinary therapy, as they exert specific 5-lipoxygenase inhibition.